검색





검색





시장가
/
주식
/
nasdaq-rgen
/

Repligen Corp

RGEN

관심 목록에 추가

107.030USD

-6.570-5.78%

종가 05/13, 16:00（ET）시세는 15분 지연됩니다

6.41B시가총액

117.17P/E TTM



Repligen Corp

107.030

-6.570-5.78%

개요 금융 토론 분석 회사

개요

금융

토론

분석

회사

자세한 내용은 Repligen Corp 회사

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Repligen Corp 정보



종목 코드 RGEN

회사 이름Repligen Corp

상장일Apr 29, 1986

CEOLoeillot (Olivier)

직원 수1778

유형Ordinary Share

회계 연도 종료Apr 29

주소Building 1, Suite 100

도시WALTHAM

증권 거래소NASDAQ OMX - NASDAQ BASIC

국가United States of America

우편 번호02453

전화17814499560

웹사이트https://www.repligen.com/

종목 코드 RGEN

상장일Apr 29, 1986

CEOLoeillot (Olivier)

Repligen Corp의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Ms. Karen A. Dawes

Lead Independent Director

91.82K

+0.87%

Mr. Glenn P. Muir

Independent Director

39.06K

+6.23%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

9.42K

-28.60%

Mr. Nicolas M. Barthelemy

Independent Director

4.44K

-11.24%

Mr. Rohin Mhatre, Ph.D.

Independent Director

4.02K

+17.44%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

2.22K

-155.54%

Mr. Tony John Hunt

Executive Chairman of the Board

Ms. Carrie Eglinton Manner

Independent Director

Mr. James R. Bylund

Chief Operating Officer

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

이름

이름/직위

직위

주식 보유

변동

Ms. Karen A. Dawes

Lead Independent Director

91.82K

+0.87%

Mr. Glenn P. Muir

Independent Director

39.06K

+6.23%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

9.42K

-28.60%

Mr. Nicolas M. Barthelemy

Independent Director

4.44K

-11.24%

Mr. Rohin Mhatre, Ph.D.

Independent Director

4.02K

+17.44%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

2.22K

-155.54%

수익 분석

통화: USD마지막 업데이트: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

사업별USD

이름

수익

비율

Product revenue - Filtration products

402.79M

54.58%

Product revenue-Chromatography products

153.18M

20.76%

Product revenu - Protein products

97.44M

13.20%

Product revenue-Process analytics products

81.24M

11.01%

Other

3.32M

0.45%

지역별USD

이름

수익

비율

North America

361.60M

49.00%

Europe

250.91M

34.00%

APAC/Other

125.45M

17.00%

사업별

지역별

사업별USD

이름

수익

비율

Product revenue - Filtration products

402.79M

54.58%

Product revenue-Chromatography products

153.18M

20.76%

Product revenu - Protein products

97.44M

13.20%

Product revenue-Process analytics products

81.24M

11.01%

Other

3.32M

0.45%

주식 보유 통계

마지막 업데이트: 42 minutes ago

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

8.31%

T. Rowe Price Associates, Inc.

8.06%

United Capital Financial Advisors, LLC

4.91%

Roy T. Eddleman UEO

4.85%

Vanguard Capital Management, LLC

4.25%

기타

69.62%

주주

비율

BlackRock Institutional Trust Company, N.A.

8.31%

T. Rowe Price Associates, Inc.

8.06%

United Capital Financial Advisors, LLC

4.91%

Roy T. Eddleman UEO

4.85%

Vanguard Capital Management, LLC

4.25%

기타

69.62%

주주 유형

주주

비율

Investment Advisor

62.92%

Investment Advisor/Hedge Fund

38.33%

Hedge Fund

9.18%

Individual Investor

5.23%

Research Firm

1.98%

Pension Fund

1.75%

Bank and Trust

0.82%

Sovereign Wealth Fund

0.82%

Private Equity

0.56%

기관 주식 보유



마지막 업데이트: Sun, Apr 5

보고 기간

기관 수

보유 주식

비율

변동

2026Q1

1067

65.93M

116.89%

-2.64M

2025Q4

1044

63.74M

113.23%

+2.55M

2025Q3

1027

55.23M

98.12%

-6.26M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

주주 활동



이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

4.69M

8.32%

+51.74K

+1.12%

Dec 31, 2025

T. Rowe Price Associates, Inc.

4.55M

8.07%

+1.09M

+31.55%

Dec 31, 2025

United Capital Financial Advisors, LLC

2.77M

4.92%

+14.92K

+0.54%

Dec 31, 2025

Roy T. Eddleman UEO

2.74M

4.86%

-576.21K

-17.40%

Dec 31, 2025

Fidelity Management & Research Company LLC

2.36M

4.19%

+67.67K

+2.95%

Dec 31, 2025

State Street Investment Management (US)

1.72M

3.05%

-82.44K

-4.58%

Dec 31, 2025

Citadel Advisors LLC

1.39M

2.48%

-290.47K

-17.24%

Dec 31, 2025

주식 배당금



지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

데이터 없음

주식 분할



날짜

배당락일

유형

비율

데이터 없음

날짜

배당락일

유형

비율

데이터 없음

KeyAI



Repligen Corp

자세한 내용은 Repligen Corp 회사

Repligen Corp 정보

Repligen Corp의 회사 임원진

수익 분석

주식 보유 통계

기관 주식 보유

주주 활동

관련 ETF

주식 배당금

주식 분할